May 21, 2020In light of the COVID-19 pandemic and widespread stay-at-home orders, the European ADHD Guidelines Group (EAGG) has released guidance1 for patients who wish to start a new ADHD medication (specifically psychostimulants and atomoxetine) but did not complete an in-person cardiovascular assessment prior to the quarantine.
Starting a new medication under these circumstances was deemed appropriate only if three conditions are satisfied:If the first two conditions are not met, medical practitioners should postpone treatment changes until a referral to a cardiologist is issued.
If the individual with ADHD is unable to conduct baseline monitoring, the EAGG states that the prescriber must evaluate the risks and benefits of an in-person
Read more on additudemag.com